Status:
COMPLETED
Prospective Stratification of Infectious Risks in Multiple Sclerosis
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Swiss Multiple Sclerosis Society
Bangerter-Rhyner Stiftung
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
This monocentric study is to identify factors that increase the susceptibility for infections and establish a questionnaire-based infection score that allows a prospective stratification for infectiou...
Eligibility Criteria
Inclusion
- Signed informed consent form (ICF) for the InRIMS-study and Swiss MS Cohort (SMSC) and/or Serially Unified Multicenter Multiple Sclerosis Investigation (SUMMIT) study
Exclusion
- Not able to sufficiently understand the patient information and questionnaire (German language)
- MS Patients with long-term antibiotic prophylaxis
- MS Patients with known primary immunodeficiency, under chemotherapy due to any malignancy or HIV infection.
Key Trial Info
Start Date :
April 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
298 Patients enrolled
Trial Details
Trial ID
NCT04036097
Start Date
April 10 2019
End Date
December 31 2023
Last Update
April 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Department of Neurology
Basel, Switzerland, 4031